Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Prostate Cancer
Interventions
DRUG

docetaxel

docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

DRUG

gemcitabine hydrochloride

IV over 30 minutes on days 1 and 8 followed by docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00276549 - Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter